‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel
SELLAS Life Sciences (SLS) reported that its REGAL trial of the galinpepimut-S cancer vaccine met the primary overall survival endpoint, with median survival of 24 months vs. 14.7 months for the best available treatment. Shares jumped over 200% on the news. Former pharmaceutical executive Martin Shkreli criticized the data, comparing it to Capricor Therapeutics' (CAPR) Deramiocel data and predicting FDA rejection.
How this was made
The 30-second read
Why it matters
For SLS, the actionable driver is the newly reported primary OS endpoint plus immediate narrative pushback that can affect near-term positioning until secondary analyses are presented. For CAPR, the actionable driver is the specific upcoming FDA decision date and a bearish public opinion that can influence sentiment and options pricing.
Market read
This is a biotech catalyst-and-narrative story: a fresh OS endpoint for SLS triggers a surge, while Shkreli’s critique raises fragility concerns; CAPR faces a near-term FDA decision with added bearish commentary.
What to watch
The article does not detail hazard ratios, confidence intervals, or the fragility index definition; traders may be reacting to narrative rather than full statistical context, and SLS’s FDA application timing is not until first half of 2027.
Background
The piece centers on Shkreli’s skepticism after SELLAS reported primary overall survival success in its REGAL trial, and it draws a comparison to Capricor’s Deramiocel ahead of an FDA decision by Nov. 22.
Ticker impact
SELLAS reported late-stage REGAL trial met the primary overall survival endpoint, with median survival 24 months vs 14.7 months, driving a sharp jump in shares.
Likely two-way trading as investors weigh the positive OS endpoint against concerns about fragility and pending secondary analyses and FDA timing.
The article contains a fresh clinical-trial primary endpoint disclosure plus a same-day high-profile critique that could swing sentiment before conference/publication and the 2027 FDA filing window.
Capricor’s Deramiocel FDA decision is expected by Nov. 22, and Shkreli argues the agency will not approve it, linking the debate to Deramiocel data.
Likely downside pressure or elevated implied volatility if traders treat the commentary as a bearish signal ahead of the FDA decision.
While the article does not add new Deramiocel trial facts, it highlights a specific upcoming regulatory date and a direct bearish claim that can move positioning.
Market effects
Reinforces high sensitivity of oncology vaccine and cell-therapy names to overall survival endpoint interpretation and fragility narratives.
Primarily US biotech sentiment; no direct macro release or cross-asset catalyst described.
Limited, mostly affects US-listed biotech risk appetite around FDA decision timelines.
Counterpoint
Shkreli’s “fragile” framing may overstate the risk; the company is still pursuing secondary endpoint analyses and planned conference and publication, which can clarify robustness.
Key entities
- companySELLAS Life Sciences
Reported REGAL trial met the primary overall survival endpoint in relapsed AML second remission, with median survival 24 months vs 14.7 months.
- companyCapricor Therapeutics
Deramiocel FDA decision expected by Nov. 22; Shkreli opined the drug will not be approved.
- personMartin Shkreli
Publicly criticized SLS results as statistically fragile and compared them to Deramiocel data.


